522 filings
8-K
QLGN
Qualigen Therapeutics Inc
16 Apr 24
Entry into a Material Definitive Agreement
4:10pm
10-K
2023 FY
QLGN
Qualigen Therapeutics Inc
Annual report
5 Apr 24
9:59pm
NT 10-K
QLGN
Qualigen Therapeutics Inc
1 Apr 24
Notice of late annual filing
2:35pm
8-K
QLGN
Qualigen Therapeutics Inc
28 Mar 24
Termination of a Material Definitive Agreement
4:05pm
8-K
QLGN
Qualigen Therapeutics Inc
27 Feb 24
Entry into a Material Definitive Agreement
7:00am
8-K
QLGN
Qualigen Therapeutics Inc
22 Feb 24
Entry into a Material Definitive Agreement
4:10pm
8-K
QLGN
Qualigen Therapeutics Inc
7 Dec 23
Entry into a Material Definitive Agreement
4:15pm
8-K
QLGN
Qualigen Therapeutics Inc
22 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
QLGN
Qualigen Therapeutics Inc
14 Nov 23
Qualigen Therapeutics Provides Corporate Update for Third Quarter and To Date 2023
5:10pm
10-Q
2023 Q3
QLGN
Qualigen Therapeutics Inc
Quarterly report
14 Nov 23
12:00am
8-K
QLGN
Qualigen Therapeutics Inc
8 Nov 23
Qualigen Therapeutics Announces First Patient Dosed in the Phase 1a Clinical Trial of QN-302 for Treatment of Advanced or Metastatic Solid Tumors
2:16pm
8-K
QLGN
Qualigen Therapeutics Inc
17 Oct 23
Regulation FD Disclosure
8:30am
S-1/A
QLGN
Qualigen Therapeutics Inc
IPO registration (amended)
2 Oct 23
8:04pm
424B3
QLGN
Qualigen Therapeutics Inc
29 Sep 23
Prospectus supplement
4:30pm
8-K
QLGN
Qualigen Therapeutics Inc
28 Sep 23
Entry into a Material Definitive Agreement
4:15pm
EFFECT
QLGN
Qualigen Therapeutics Inc
8 Sep 23
Notice of effectiveness
12:15am
POS AM
QLGN
Qualigen Therapeutics Inc
1 Sep 23
Prospectus update (post-effective amendment)
4:15pm
8-K
QLGN
Qualigen Therapeutics Inc
15 Aug 23
Results of Operations and Financial Condition
10:04am
10-Q
2023 Q2
QLGN
Qualigen Therapeutics Inc
Quarterly report
14 Aug 23
4:16pm
8-K
QLGN
Qualigen Therapeutics Inc
4 Aug 23
Departure of Directors or Certain Officers
4:30pm